Introduction {#S0001}
============

Posttranscriptional regulation of gene expression is exerted by small regulatory RNAs (sRNAs) (rev. in \[[1](#CIT0001)--[4](#CIT0004)\]). SR1 is a dual-function sRNA from *Bacillus subtilis* \[[5](#CIT0005)\]. It base-pairs with *ahrC* mRNA encoding the transcriptional activator of the arginine catabolic operons *rocABC* and *rocDEF* and inhibits its translation \[[6](#CIT0006)--[8](#CIT0008)\]. In addition, SR1 codes for the small peptide SR1P that interacts with GapA \[[9](#CIT0009)--[11](#CIT0011)\]. Both functions of SR1 are remarkably conserved over one billion years of evolution \[[12](#CIT0012)\]. Previously, we found that the abundant RNA chaperone Hfq bound both SR1 and *ahrC* mRNA, but did not stabilize either RNA nor did it promote the interaction between both complementary molecules. Instead, Hfq was required for *ahrC* translation by opening a double-stranded region near the SD sequence \[[8](#CIT0008)\]. So far, no other RNA-binding protein was found in Gram-positive bacteria that could replace Hfq in promoting the interaction between partially complementary sRNAs and their target RNAs.

CsrA (carbon storage regulator A) is a widely conserved, abundant small (≈60 aa) RNA binding protein that is involved in the regulation of carbon metabolism, biofilm formation and virulence (rev. in \[[13](#CIT0013),[14](#CIT0014)\]). CsrA binds to 2--6 sites containing single-stranded GGA motifs around the SD sequence of target mRNAs \[[15](#CIT0015)\] where it inhibits \[[16](#CIT0016),[17](#CIT0017)\] or activates translation \[[18](#CIT0018)\], influences RNA processing \[[19](#CIT0019)\] or alters transcript elongation \[[20](#CIT0020)\]. A recent integrated transcriptomics approach revealed a global role of CsrA in *E. coli* \[[21](#CIT0021)\]. Interestingly, not only the expression of 87 transcriptional regulators and 11 sensor kinases was found to be affected by CsrA, but also the abundance of 11 base-pairing sRNAs, among them GadY, Spot42, GcvB and MicL. In Gram-negative bacteria, small RNAs like CsrC or CsrB containing 13--22 CsrA binding motifs can sequester CsrA, thereby relieving repression or reversing activation of corresponding target mRNAs. In *B. subtilis*, CsrA has so far only been found to regulate one target, *hag* mRNA, and is not sequestered by an sRNA, but by a protein (FliW) \[[22](#CIT0022)\]. Thereby, FliW interacts with a C-terminal extension of CsrA and allosterically antagonizes CsrA in a non-competitive manner thus preventing CsrA binding to *hag* mRNA \[[23](#CIT0023)\].

Here, we investigate the effect of CsrA on SR1, its primary target *ahrC* mRNA and its downstream targets, the *rocABC* and *rocDEF* operons.

Results {#S0002}
=======

CsrA binds SR1 and *ahrC* mRNA in nanomolar range {#S0002-S2001}
-------------------------------------------------

Using the SELEX procedure, a consensus binding site for *E. coli* CsrA was identified. This sequence contains a critical GGA motif with less conserved nucleotides upstream and downstream. The GGA motif in natural CsrA binding sites is typically found in the loop of a short hairpin or in a single-stranded region \[[15](#CIT0015)\]. The secondary structure of SR1 \[[8](#CIT0008)\] displays three GGA motifs, motif 1 in the large bulge interrupting stem-loop I, motif 2 in the single-stranded central region and motif 3 at the base of the small central stem-loop II ([Fig. 1A](#F0001)). To investigate, whether CsrA can bind SR1, plasmid pGPPM1 was constructed allowing the purification of C-terminally Strep-tagged *B. subtilis* CsrA from *E. coli*. To exclude co-purification of Hfq, an *E. coli ∆hfq* strain was used. CsrA~Strep~ was employed in EMSA (electrophoretic mobility shift assay) with internally labelled wild-type SR1 (SR1~WT~). As shown in [Fig. 2A](#F0002), an RNA-protein complex was observed upon increasing concentrations of CsrA~Strep~. A K~d~ value of 183 nM was calculated for the SR1~WT~/CsrA complex (Fig. S2).10.1080/15476286.2019.1605811-F0001Figure 1.Secondary structures of SR1 and *ahrC~483~* mRNA.Secondary structures of SR1 (a) and *ahrC* mRNA (b) as determined before \[[8](#CIT0008)\] are shown. GGA motifs are highlighted in black and numbered. Complementary regions A to G in SR1 and A' to G' in *ahrC* mRNA are highlighted in grey. The SD sequence of *ahrC* is boxed. Mutations in GGAs of SR1 and *ahrC* are indicated.10.1080/15476286.2019.1605811-F0002Figure 2.CsrA binds to SR1 and *ahrC* mRNA.EMSA with purified internally α ^32^-P-\[UTP\] labelled RNA and increasing concentration of purified CsrA. 0.15 fmol of labelled wild-type or mutated SR1 or *ahrC* mRNA species of different size were incubated with CsrA at the indicated concentrations in a total volume of 10 µl (final RNA concentration 0.015 nM) for 10 min, followed by separation on 4% (*ahrC* RNA) or 8% (SR1) native PAA gels. The investigated mutations are indicated. Autoradiograms of the gels are shown. (a) EMSAs with wild-type and mutated SR1 species. (b) Competition EMSA with heterologous RNAIII (left) or unlabelled SR1 species (right). Above, the fold excess of the competitor RNA is indicated. (c) EMSAs with wild-type full-length *ahrC*~483~ mRNA containing 11 GGA\* motifs (left) and shortened (nt 1--136) *ahrC*~136~ mRNA containing the three 5ʹ GGA\*s (centre) as well as *ahrC*~136~ RNA mutated in the GGA\*s (right) are shown. (d) EMSAs with *ahrC*~483~ mRNA mutated in addition to GGA1\*-3\* in one other GGA\*.

To analyse the role of the individual CsrA binding motifs, SR1 species with point mutations in motif 1 (GGA to GCA, SR1~mut1~), motif 2 (GGA to GAA; SR1~mut2~) and motif 3 (GGAto GCA, SR1~mut3~) were tested ([Fig. 2A](#F0002)). SR1~mut1~ was bound by CsrA~Strep~ with nearly the same affinity as wild-type SR1. No complex was observed with SR1~mut2~, and intermediate levels of complex were observed with SR1~mut3~ suggesting that the GGA2 motif in SR1 is important. To confirm the specificity of the SR1-CsrA interaction, unlabelled heterologous RNAIII of plasmid pIP501 \[[24](#CIT0024),[25](#CIT0025)\] was used as competitor ([Fig. 2B](#F0002), left). Whereas a 10-fold excess of unlabelled SR1 could outcompete labelled SR1, a 10^4^-fold excess of RNAIII was required ([Fig. 2B](#F0002), left). When the mutated SR1 species were used in a competition assay, a 10-fold excess of SR1~mut1~ and SR1~mut3~ competed with labelled SR1~WT~, whereas a 100-fold excess of SR1~mut2~ was not able to compete with SR1~WT~ ([Fig. 2B](#F0002), right). This further corroborated the importance of GGA motif 2 in SR1.

The primary target of SR1, *ahrC* mRNA, carries 11 GGA motifs ([Fig. 1B](#F0001)), with six of them (1, 3, 7, 8, 10 and 11) in fully or partially (2 free nt) single-stranded regions. In the following, we designate the *ahrC* GGA motifs GGA\* to distinguish them from the SR1 GGA motifs. Using EMSAs, CsrA binding to full-length *ahrC*~483~ RNA and a 3ʹ truncated species, *ahrC*~136~ RNA, was tested. [Fig. 2C](#F0002) shows that both species bound CsrA with about the same affinity with a K~d~ of 405 nM (Fig. S2). *ahrC*~136~ RNA contains three 5ʹ GGA\* motifs, with two (GGA2\* and GGA3\*) adjacent to G', which is one of the seven regions (A' to G') in *ahrC* mRNA that are complementary to SR1 regions A to G (see [Fig. 1](#F0001)). The initial contact between SR1 and *ahrC* mRNA occurs between G and G' \[[7](#CIT0007)\]. Three mutated *ahrC*~136~ species were tested in EMSAs. Whereas *ahrC*~136mut1~ and *ahrC*~136mut2/3~ bound with an efficiency comparable to the wild-type, only *ahrC*~136~ carrying mutations in all three GGA\*s (GGA1\*-3\* to GCA) was unable to bind CsrA ([Fig. 2C](#F0002)). However, full-length *ahrC*~483~ carrying mutations in GGA1\*-3\* still bound CsrA ([Fig. 2D](#F0002)). Therefore, we mutated GGA\*s 6, 7, 8 and 10 individually to GCA in *ahrC*~483~ species lacking GGA1\* to 3\* and assayed these mutant RNAs for CsrA binding ([Fig. 2D](#F0002)). No decrease in binding was detected. This suggests that several GGA\* motifs may be required for CsrA binding.

CsrA induces slight structural changes in *ahrC* mRNA {#S0002-S2002}
-----------------------------------------------------

To analyse whether binding of CsrA induces structural alterations in SR1, a detailed footprinting experiment with RNases T1, T2 and A was performed ([Fig. 3A](#F0003)). Except the expected protection at GGA2, no structural changes were observed. The importance of single GGA motifs for CsrA binding was further investigated by comparative footprinting with RNase T1 on 5ʹ-labelled SR1~WT~, SR1~mut1~ and SR1~mut2~ in the presence or absence of CsrA. Only SR1 GGA2, but not GGA1 or GGA3, was protected by CsrA ([Fig. 3B](#F0003)) corroborating the EMSA results. As expected, no protection in SR1~mut2~ by CsrA was observed ([Fig. 3C](#F0003)). An RNase T1, T2, A and nuclease S1 footprinting experiment was also carried out with *ahrC*~136~ RNA containing the SD sequence, start codon and GGA1\* to 3\* ([Fig. 3D](#F0003)). All GGA\*s showed a clear protection by CsrA which agreed with the EMSA results. No alterations were visible at the SD sequence (not shown). By contrast, distinct changes were observed upstream of GGA2\*: C~113~ and U~118~ that are base-paired in the absence of CsrA, became single-stranded in its presence as shown by RNase A, and, to a lower extent, nuclease S1 and RNase T2 cuts. This makes the 6 nt long region G', which is base-paired in the absence of CsrA more accessible for the initial interaction with SR1 region G. The data are summarized in [Fig. 3E](#F0003). To study possible further structural changes, full-length *ahrC*~483~ RNA was subjected to partial digestion with RNase T1 in the presence and absence of CsrA (Fig. S3). Although the resolution of this gel does not allow visualization of each individual GGA\*, no alterations in the general RNase T1 cleavage pattern could be observed at the GGA motifs downstream of GGA3\*.10.1080/15476286.2019.1605811-F0003Figure 3.RNase footprinting of SR1 and *ahrC*~136~ mRNA at increasing concentrations of CsrA.Secondary structure probing of 5ʹ labelled SR1 with RNases T1, T2 and A (a) and wild-type (b) and two SR1 mutants with RNases T1 (c) after binding of increasing concentrations of CsrA was performed as described in *Materials and Methods*. (d) Secondary structure probing of 5ʹ labelled *ahrC~136~* mRNA with RNases T1, T2, A and nuclease S1 after binding of increasing amounts of CsrA. Red dots indicate enhanced protection, green dots better accessibility upon CsrA binding. Autoradiograms of the gels are shown. TL and T1L, T1 cleavage under denaturing conditions. OH, alkaline ladder. Bars indicate the positions of the GGA motifs. (e) Secondary structure of *ahrC*~136~ RNA as probed previously \[[8](#CIT0008)\]. The SD sequence is boxed; CsrA binding motifs are highlighted in black and region G' for the initial interaction with SR1 in grey. Red and green residues indicate enhanced protection or accessibility, respectively, according to the autoradiogram shown in (d).

CsrA does not affect the stability of SR1 or *ahrC* mRNA {#S0002-S2003}
--------------------------------------------------------

A recent transcriptomics study revealed that CsrA affects the stability of more than 200 RNAs in *E. coli* \[[21](#CIT0021)\]. We analysed the influence of CsrA binding on the stability of SR1 or *ahrC* mRNA. To determine the SR1 half-life in the presence and absence of CsrA we performed Northern blotting with *B. subtilis* DB104 and its isogenic *∆csrA* strain. In both strains, the half-life was about 3.5 to 4 min indicating that CsrA does not affect the stability of SR1 ([Fig. 4A](#F0004)). As *ahrC* mRNA was not detectable in Northern blots, we applied qRT-PCR to determine its half-life in DB104, DB104*(∆csrA*) and DB104(*∆sr1*). The half-life in DB104 and DB104*(∆csrA*) was 1.5 to 2 min ([Fig. 4B](#F0004)). In addition, qRT-PCR corroborated our previous result \[[7](#CIT0007)\] that binding of SR1 does not promote the degradation of *ahrC* mRNA. Only a slight (1.5-fold) effect on the half-life of *ahrC* mRNA was detectable in DB104(*∆sr1*).10.1080/15476286.2019.1605811-F0004Figure 4.Effects of CsrA on the stability of both SR1 and *ahrC* mRNA and on *ahrC* translation.(a) The half-life of SR1 was determined in wild-type strain DB104 and in the isogenic *∆csrA* strain after rifampicin addition and Northern blotting as described in *Materials and Methods*. (b) The half-life of *ahrC* mRNA was determined by qRT-PCR as described in *Materials and Methods*. In both cases, cultures were grown in complex TY medium to OD~600~ = 4.5. The average values obtained from three biological replicates with standard deviations are shown. (c) *In vitro* translation of *ahrC* in the presence and absence of CsrA and/or SR1. *In vitro* translation was performed as described in *Materials and Methods*. Used amounts of CsrA, SR1~start\ to\ stop~ and *ahrC* RNA are indicated. Below, the amounts of synthesized protein relative to the reaction only containing the *ahrC* template are shown. (d) Translational *ahrC-lacZ* fusions under the constitutive promoter pI were integrated into the *amyE* locus of *B. subtilis* DB104, DB104 (*∆csrA*), DB104 (*∆sr1*) as well as DB104 (*∆sr1* pWSR1) and DB104 (*∆sr1 ∆csrA* pWSR1). β-galactosidase activities were measured after growth in TY medium at OD~600~ = 4.5. In all cases, the indicated values are the results of three biological replicates. Error bars represent standard deviations. Control, vector pGAB1 with promoterless *lacZ* integrated into the *amyE* locus. Induction, *sr1* transcription from pWSR1 was induced with 0.2 µg/ml anhydrotetracycline.

CsrA does not influence the translation of *ahrC* mRNA directly {#S0002-S2004}
---------------------------------------------------------------

Since CsrA bound to *ahrC* mRNA and SR1 but did not alter their stability, we asked whether it directly affects *ahrC* translation. To investigate this issue, we employed *in vitro* translation ([Fig. 4C](#F0004)). *In vitro* transcribed and purified *ahrC* mRNA was used as template and either *in vitro* transcribed and purified SR1~start\ to\ stop~ or purified CsrA~Strep~ or both were added. We used an amount of CsrA that almost completely bound *ahrC*~483~ RNA in the previous EMSA ([Fig. 2C](#F0002)). No significant differences in the amounts of AhrC protein were observed with or without CsrA~Strep~. As expected from our previous data \[[7](#CIT0007)\], addition of SR1 resulted in a three-fold decrease of AhrC confirming that SR1 directly inhibits *ahrC* translation. Lanes 6 to 9 show a direct correlation between the amounts of added *ahrC* mRNA and the obtained translation product. In summary, CsrA does not appear to influence the translation of *ahrC* mRNA directly.

To substantiate this result *in vivo, B. subtilis* wild-type strain DB104 with a translational *ahrC*~483~*-lacZ* fusion in the *amyE* locus was constructed as described in *Materials and Methods*. The *ahrC*~483~-*lacZ* fusion contains all 11 GGA\*s and all regions complementary to SR1. Since the native *ahrC* promoter is extremely weak (*ahrC* mRNA is not detectable in Northern blots, see above) and overexpression of *ahrC* is toxic, the moderate constitutive *copR* promoter pI \[[24](#CIT0024),[26](#CIT0026)\] was employed for *ahrC* transcription. DB104 (*amyE*::pI-*ahrC-lacZ*) was used as recipient strain for transformation with chromosomal DNA from *∆csrA* or the *∆sr1* strains and with *sr1* overexpression plasmid pWSR1 (≈50 copies/cell). Five transformants of each strain were grown in parallel in TY medium to OD~600~ = 4.5 and β-galactosidase activities measured ([Fig. 4D](#F0004)). No alterations in the *∆csrA* strain were observed compared to the wild-type strain, suggesting that CsrA does not affect the translation of *ahrC*. No difference was seen in the case of the *∆sr1* strain because of the higher strength of pI compared to the native *ahrC* promoter. The amount of SR1 transcribed from its native promoter appears to be too low to significantly affect translation of the *ahrC* mRNA from *amyE*::pI-*ahrC-lacZ*. However, using pWSR1 for transcription of SR1 in excess over *ahrC* mRNA, a five- to six-fold reduction in β-galactosidase activity was observed ([Fig. 4D](#F0004)). In the *∆csrA* background, with pWSR1, only a three-fold decreased β-galactosidase activity was measured ([Fig. 4D](#F0004)). Induction vs. no induction of *sr1* transcription from pWSR1 confirms that the effect on *ahrC* translation is indeed due to SR1. Taken together, both *in vitro* and *in vivo* data show that CsrA does not affect the translation of *ahrC* mRNA directly whereas SR1 does.

CsrA promotes the base-pairing interaction between SR1 and *ahrC* mRNA {#S0002-S2005}
----------------------------------------------------------------------

SR1 and its primary target *ahrC* mRNA share seven short stretches of complementarity designated A to G and A' to G', respectively (\[[6](#CIT0006),[7](#CIT0007)\], [Fig. 1](#F0001)). As CsrA was able to bind both RNAs with a similar affinity ([Fig. 2](#F0002)), we asked whether it promotes their base-pairing. To this end, SR1/*ahrC* mRNA complex formation was studied by EMSA in the presence and absence of 1 µM CsrA. Labelled SR1 and increasing concentrations (between 25 and 400 nM) of unlabelled *ahrC* RNA were used ([Fig. 5A](#F0005)). In the second experiment, labelled *ahrC* mRNA and the same increasing concentrations of unlabelled SR1 were employed ([Fig. 5B](#F0005)). In the absence of CsrA, only about 33% of the labelled RNA were present in the complex at the highest concentration of unlabelled complementary RNA. By contrast, in the presence of CsrA, the amount of the SR1/*ahrC* mRNA complex increased in both experiments significantly, two-fold for labelled SR1, and two- to three-fold for labelled *ahrC* mRNA. Thus, CsrA appears to bind both RNAs and facilitates their base-pairing.10.1080/15476286.2019.1605811-F0005Figure 5.SR1/*ahrC* mRNA complex formation in the presence and absence of CsrA.In both cases, 1 µM CsrA was employed if indicated and complex formation monitored in 6% native PAA gels as described in *Materials and Methods*. The labelled RNAs (0.15 fmol per reaction) were used in at least 100-fold lower equimolar amounts than the unlabelled RNAs. (a) Complex formation between internally α-^32^P-\[UTP\]-labelled SR1 and unlabelled full-length *ahrC~483~* mRNA. Used *ahrC* mRNA concentrations are indicated. (b) Complex formation between internally α-^32^P-\[UTP\]-labelled full-length *ahrC~483~* mRNA and unlabelled SR1. Used SR1 concentrations are indicated.

The analysis ofAhrC target promoters *p*~rocABC~ and *p*~rocDEF~ demonstrates the concerted action of CsrA, *ahrC* mRNA and SR1 *in* *vivo* {#S0002-S2006}
-------------------------------------------------------------------------------------------------------------------------------------------

AhrC is the transcriptional activator of the arginine catabolic operons *rocABC* and *rocDEF* \[[27](#CIT0027)\]. Previously, we have shown that in the absence of SR1, the amount of the downstream targets *rocABC* and *rocDEF* mRNA was four-fold and seven-fold increased, respectively \[[7](#CIT0007)\]. This was due to SR1 inhibiting the translation of *ahrC* mRNA \[[8](#CIT0008)\]. To investigate whether CsrA has an effect on the transcription of both *roc* operon mRNAs by promoting SR1/*ahrC* base-pairing, transcriptional p*~rocABC~*- and p*~rocDEF~-lacZ* fusions were constructed and integrated into the *amyE* locus of DB104, DB104(*∆csrA*), DB104(*∆ahrC*), DB104 (*∆ahrC ∆csrA*), DB104(*∆sr1*), DB104(*∆sr1 ∆csrA*), DB104(*∆sr1* pGKSR1) as well as DB104(*∆sr1 ∆csrA* pGKSR1). Cells were grown in complex TY medium to OD~600~ = 4.5 where both *sr1* and *csrA* levels are high (\[[8](#CIT0008)\]; Fig. S4) and β-galactosidase activities measured ([Fig. 6A](#F0006)). The activities of p*~rocABC~* and p*~rocDEF~* were approximately 4.5-fold higher in the *csrA* knockout strain. In the *∆ahrC ∆csrA* strain, promoter activities decreased to wild-type level suggesting that CsrA exerts its effect via *ahrC* RNA. In the *sr1* knockout strain, promoter activities were five- to six-fold higher than in the wild-type. This agrees with a previous report that levels of both *roc*-operon mRNAs are enhanced in the absence of SR1 \[[7](#CIT0007)\]. In the *∆sr1 *∆*csrA* strain, no further increase of p*~rocABC~* and p*~rocDEF~* activities was observed compared to either single-knockout indicating that both SR1 and CsrA act on the same regulatory level. Overexpression of *sr1* from pGKSR1 partially compensated for the lack of CsrA. Promoter activities were two-fold lower than in the *∆sr1 ∆csrA* strain, which is in good agreement with the data shown in [Fig. 5B](#F0005). High SR1 concentrations resulted in high amounts of SR1/*ahrC* RNA complex in the absence of CsrA whereas at low SR1 concentrations, CsrA was required to obtain comparable amounts of SR1/*ahrC* RNA complex. The results of these β-galactosidase measurements demonstrate that the effect of CsrA on SR1/*ahrC* complex formation measured *in vitro* is also important *in vivo*. In addition, we compared the p*~rocABC~* and p*~rocDEF~* activities in the presence and absence of CsrA in CSE minimal medium in the presence of L-arginine, since AhrC is only active when L-arginine is present. As shown in Fig. S5, the activity of both promoters is about 2.5-fold higher in the absence of CsrA, confirming the effects observed in TY medium as well as the increase in the amount of SR1/*ahrC* mRNA complex in the presence of CsrA ([Fig. 5](#F0005)).10.1080/15476286.2019.1605811-F0006Figure 6.Effects of CsrA on the transcription from *rocABC* and *rocDEF* promoters.Transcriptional p*~rocABC~-lacZ* and p*~rocDEF~-lacZ* fusions were integrated into the *amyE* locus of *B. subtilis* and β-galactosidase activities measured after growth in TY medium until stationary phase at OD~600~ = 4.5. The indicated values are the results of three biological replicates. Error bars represent standard deviations. (a) DB104 wild-type and the indicated isogenic knockout and overexpression strains were used. (b) Effects of mutations in SR1 GGA2 and *ahrC* GGA1\* and GGA3\*. The indicated strains were used. VC, vector pMG16 with promoterless *lacZ* integrated into the *amyE* locus.

In [Fig. 2](#F0002) we have shown that CsrA binds to GGA1\* to GGA3\* in *ahrC* mRNA and to GGA2 in SR1. All 5ʹ GGA\*s in *ahrC* mRNA are located in the coding sequence. Therefore, only motifs GGA1\* and 3\*, but not GGA2\*, can be mutated without altering the *ahrC* ORF. To confirm the effect of CsrA on *ahrC in vivo* and to analyse the effect of GGA1\* and 3\*, GGA1\* was replaced by AGA and GGA3\* by GGG. These mutations ensure that the *ahrC* ORF is maintained, the SR1 binding sites are not affected and the structure of the stem-loop in *ahrC* mRNA is not altered. Mutations were introduced into the chromosomal *ahrC* gene expressed under its native promoter yielding strain DB104 (*ahrC~mut1/3~*). p*~rocABC~* activities of this strain were investigated in the presence and absence of CsrA with or without *sr1* overexpression from pGKSR1 ([Fig. 6B](#F0006)). For comparison, the relevant strains analysed in [Fig. 6A](#F0006) were grown in parallel. Although identical AhrC proteins were synthesized, p*~rocABC~* activities were 4.5-fold higher in the presence of mutated *ahrC* compared to wild-type *ahrC* indicating that either SR1 or CsrA bound less efficiently to *ahrC~mut1/3~* mRNA, inhibiting its translation. When CsrA was absent, no significant differences between wild-type and *ahrC~mut1/3~* were visible suggesting that CsrA was responsible. This was confirmed for p*~rocABC~* in the presence and absence of CsrA when GGA1\* and GGA3\* were mutated in *ahrC*. Overexpression of *sr1* in the presence of CsrA resulted in p*~rocABC~* activities that were three-fold lower in the *ahrC* wild-type than in the *ahrC~mut1/3~* strain. No significant differences were found in the *ahrC~mut1/3~* strain in the presence or absence of CsrA whereas a three-fold difference was observed when *ahrC* RNA carried the wild-type CsrA binding motifs suggesting that the absence of *csrA* has the same effect as the loss of two 5ʹ CsrA binding sites in *ahrC*. These data provide compelling evidence that CsrA binds to *ahrC* mRNA *in vivo* and that CsrA binding sites GGA1\* and GGA3\* play an important role.

To investigate the *in vivo* role of GGA2 in SR1, pGKSR1~mut2~ was used to analyse p*~rocABC~* transcriptional fusions. In the absence of CsrA, pGKSR1~mut2~ showed an intermediate effect comparable to pGKSR1 ([Fig. 6B](#F0006)). A comparison between the *sr1* and the *sr1~mut2~* overexpression strains in the presence of CsrA revealed a ≈ 1.5-fold higher p*~rocABC~* activity, indicating that binding of SR1~mut2~ to *ahrC* mRNA or to CsrA was slightly affected. When *csrA* was deleted in both strains, a similar (2.7-fold vs. 2.2-fold) increase in p*~rocABC~* activity was observed for pGKSR1 compared to pGKSR1~mut2~. This suggests that binding of CsrA to motif 2 in SR1 is not crucial for the regulation of *ahrC* downstream targets.

Taken together, these data show that SR1, *ahrC* mRNA and CsrA act in concert to regulate the arginine catabolic operons. Thereby, CsrA binding to *ahrC* mRNA is required for SR1-dependent regulation of the *roc* operons whereas CsrA binding to SR1 plays only a minor role.

CsrA has no effect on the translation of *rocA, rocD* or *ccpN* {#S0002-S2007}
---------------------------------------------------------------

To exclude additional direct effects of CsrA on the translation of *rocA* or *rocD*, the first ORFs of the *rocABC* and *rocDEF* operons, respectively, translational *rocA-lacZ* and *rocD-lacZ* fusions were constructed under control of constitutive heterologous promoter pIII \[[24](#CIT0024)\] ([Fig. 7A](#F0007)). They were integrated into the *amyE* locus of DB104 and DB104 (*∆csrA*) and β-galactosidase activities measured in TY medium. Upon using heterologous promoter pIII it is apparent that CsrA does not affect *rocA* or *rocD* translation ([Fig. 7B](#F0007)).10.1080/15476286.2019.1605811-F0007Figure 7.Effects of CsrA on the translation of *rocA, rocD* and *ccpN.*(a) Schema of the pIII-*rocA-lacZ* fusion. Heterologous promoter pIII used to replace p*~rocABC~* is followed by the 5ʹ UTR of *rocA (rocD, ccpN)*, the SD and the first 17 codons of the corresponding ORF fused in frame to the 2^nd^ *lacZ* codon. (b) Translational *rocA-lacZ, rocD-lacZ*, and *ccpN-lacZ* fusions were integrated into the *amyE* locus of *B. subtilis* DB104 or DB104 *(∆csrA*) and β-galactosidase activities measured after growth in TY medium until OD~600~ = 4.5. In all cases, the indicated values are the results of three biological replicates. Error bars represent standard deviations.

SR1 is regulated by CcpN, a transcription factor that represses *sr1* transcription under glycolytic conditions \[[6](#CIT0006)\] by binding to two sites upstream of the −35 and overlapping the −10 box of the *sr1* promoter \[[28](#CIT0028)--[30](#CIT0030)\]. To rule out that the SR1 levels were additionally altered by direct binding of CsrA to *ccpN* mRNA, a translational pIII-*ccpN-lacZ* fusion was constructed and measured as above. Again, no difference in *ccpN* translation was detected between wild-type and *csrA* knockout strain ([Fig. 7](#F0007)).

Therefore, we can conclude that CsrA has only an effect on the promoter activity of the downstream target operons of SR1, but does not influence the translation of their genes directly.

*sr1* overexpression impairs the use of arginine as carbon source, but additional deletion of *csrA* restores wild-type growth {#S0002-S2008}
------------------------------------------------------------------------------------------------------------------------------

The target of the *sr1/ahrC/csrA* regulatory system is arginine catabolism. To answer the questions, whether *sr1* overexpression impairs the use of L-arginine as carbon source and whether deletion of *csrA* can compensate this effect, we analysed growth in liquid minimal media with different carbon sources. *B. subtilis* wild-type, *∆ahrC, ∆sr1, ∆csrA* strains, a strain for constitutive overexpression of *sr1* from plasmid pGKSR1 in the *∆sr1* background and a *∆csrA ∆sr1* pGKSR1 strain were grown in glucose-free CSE minimal medium and in CSE with L-arginine (CSEA) or glucose (CSEG) as additional carbon sources. In all cases, succinate and glutamate were provided to allow basal growth. The growth curves in [Fig. 8A](#F0008) clearly show that all strains grew slowly in CSE and quickly in CSEG. In CSEA, the *∆ahrC* strain and the *∆sr1* pGKSR1 strain (downregulation of *ahrC* by *sr1* overexpression) showed impaired growth after exhaustion of succinate and glutamate suggesting that L-arginine cannot be used as sole carbon source. Deletion of *csrA* in the *sr1* overexpression strain (*∆csrA ∆sr1* pGKSR1) compensated for the *sr1* overexpression effect and restored wild-type growth. These results are consistent with the *in vitro* effects of CsrA on the interaction between SR1 and *ahrC* mRNA.10.1080/15476286.2019.1605811-F0008Figure 8.Effects of CsrA and *sr1* overexpression on the growth of *B. subtilis* in CSE minimal medium with different carbon sources.(a) *B. subtilis* strain DB104 and its isogenic *∆sr1, ∆ahrC, ∆csrA* mutants as well as *∆ahrC*/*∆csrA, ∆sr1*(pGKSR1) and *∆sr1*/*∆csrA*(pGKSR1) strains were inoculated at OD~600~ = 0.1 into CSE minimal medium or CSE supplemented with either glucose (CSEG) or arginine (CSEA) as additional carbon source and growth monitored over 8 h. (b) Investigation of the effects of mutated CsrA binding sites in SR1 (pGKSR1~mut2~) and *ahrC* mRNA (*ahrC~mut1/3~*) on growth in CSEA. The indicated strains were used. Growth curves in CSE and CSEG are identical and not shown. Data shown with standard deviations (error bars are very small) are the results of four biological replicates.

To corroborate an effect of CsrA on SR1, we compared the growth of *∆sr1* strains containing pGKSR1~mut2~ or pGKSR1 in the presence and absence of CsrA. The growth of all strains in CSE and CSEG was similar (not shown). In CSEA mutation of the decisive GGA2 motif of SR1 had an intermediate effect (slight growth impairment) between wild-type, overexpression (pGKSR1) and knockout (*∆sr1*) strains in the presence of CsrA compared to its absence ([Fig. 8B](#F0008) left). This indicates that either SR1~mut2~ bound less efficiently to *ahrC* mRNA or that binding of CsrA to SR1 plays at least a minor role.

To investigate an effect of mutated GGA1\* and GGA3\* in *ahrC* mRNA, DB104 (*ahrC~mut1/3~)* was analysed in the presence and absence of CsrA as well as pGKSR1 for growth in CSE, CSEG and CSEA as above. Again, all strains grew identically in CSE and CSEG (not shown). In CSEA, the *∆ahrC* strain showed impaired growth in the presence of CsrA as above ([Fig. 8B](#F0008) right). In the absence of CsrA, all strains grew identically. If binding of CsrA to GGA1\* and GGA3\* in *ahrC* mRNA is required for initial contact with SR1, *sr1* overexpression should not compensate for the *ahrC~mut1/3~* mutations in the presence of CsrA. Whereas overexpression of SR1 decreased the growth of the wild-type strain DB104, it did not affect the growth of the *ahrC~mut1/3~* mutant strain confirming our hypothesis. A comparison between *ahrC~mut1/3~* in the presence and absence of CsrA showed no growth difference, which agrees with the finding that CsrA cannot bind *ahrC~mut1/3~* mRNA *in vivo.*

In conclusion, CsrA is an integral part of the *sr1/ahrC* regulatory system *in vivo* as demonstrated in [Fig. 8](#F0008).

EMSAs with mutated SR1 and *ahrC* mRNA species suggest a mechanism of action for CsrA {#S0002-S2009}
-------------------------------------------------------------------------------------

To unravel how CsrA promotes complex formation between SR1 and *ahrC* mRNA, we performed EMSAs with combinations of internally labelled wild-type and mutated SR1 and unlabelled wild-type and mutated *ahrC* mRNA species.

Our previous structure probing analysis of SR1, *ahrC* mRNA and the SR1/*ahrC* RNA complex revealed that both RNAs fold in a modular way whereby the structure of the 5ʹ proximal region of either RNA was the same as in longer species \[[7](#CIT0007)\]. Although binding factors like CsrA immediately associate upon RNA synthesis, we believe that the above finding allows to use preformed RNA in the EMSA described below.

As shown in [Fig. 9A](#F0009) (a repetition of the experiment in [Fig. 5A](#F0005)) CsrA enhances complex formation about two-fold between wild-type SR1 and *ahrC* mRNA. This is in good agreement with the ≈4.5-fold effect of CsrA on the p*~roc~* activities ([Fig. 6A](#F0006)). Surprisingly, the same result was obtained when SR1~mut2~ was paired with wild-type *ahrC* mRNA. Complex formation with and without CsrA was 30% less efficient than in the case of SR1~WT~, because SR1 GGA2 overlaps region C, which is complementary with region C' in *ahrC* ([Fig. 1](#F0001)). However, despite the interruption of complete base-pairing by the GGA2 mutation, CsrA was able to overcome this defect at 400 nM *ahrC* mRNA with the amount of complex increasing from 24 to 42% ([Fig. 9B](#F0009)). This suggests that CsrA enhances SR1/*ahrC* mRNA complex formation without the requirement to bind to SR1. As expected from our data in [Fig. 2A](#F0002), no SR1-CsrA complex was visible. GGA1\* in *ahrC* is located outside of region G' that is required for the initial contact with SR1. Therefore, *ahrC~mut1~* RNA was as efficient as wild-type *ahrC* mRNA in binding SR1~WT~ in the absence of CsrA ([Fig. 9C](#F0009)). However, CsrA was no longer capable of enhancing complex formation, suggesting that GGA1\* in *ahrC* mRNA is crucial for promotion of complex formation by CsrA. Binding of *ahrC*~mut2+3~ RNA to SR1~WT~ ([Fig. 9D](#F0009)) was significantly impaired in the absence of CsrA (10% compared to 38%), as GGA2\* and GGA3\* are adjacent to complementary region G' (see [Fig. 1](#F0001)). CsrA could not overcome this pairing deficiency, and, thus, GGA2\* and GGA3\* are also important for CsrA enhancing *ahrC* mRNA/SR1 complex formation. Furthermore, both in the presence and the absence of CsrA, complex formation between SR1 and *ahrC*~mut1/2/3~ RNA was significantly three- to four-fold impaired, as both complementary region G' and the essential CsrA binding motifs were affected (Fig. S6). As a negative control, *ahrC*~mut6~ RNA was employed (Fig. S6). This mutant still contains the important motifs GGA1\*-3\* and all complementary regions to SR1. Therefore, the SR1/*ahrC* mRNA complex formation is enhanced ≈1.7-fold in the presence of CsrA. In all instances except SR1~mut2~, CsrA bound SR1 as expected ([Fig. 9A--D](#F0009), Fig. S6). Since pGKSR1~mut2~ behaved similarly to pGKSR1 in the presence or absence of CsrA in regulating the p*~rocABC~* activity ([Fig. 6B](#F0006)), the combination of *in vitro* and *in vivo* data suggests the following mechanism presented in [Fig. 10A](#F0010): CsrA first binds GGA1\* in *ahrC* mRNA. This facilitates binding of GGA3\* in *ahrC* RNA, which had blocked the stem-loop of the decisive G' region. Binding of CsrA to motifs 1 and 3 induces slight structural alterations in *ahrC* mRNA that make region G' accessible to binding of complementary SR1 region G (see [Fig. 3D](#F0003)). Subsequently, the other complementary regions A to F in SR1 and A' to F' in *ahrC* mRNA interact with each other. We hypothesize that even though CsrA binding motif 2 in SR1 is not needed for the SR1/*ahrC* mRNA contact it might be involved in forming a bridge to one of the downstream motifs in *ahrC* mRNA to promote this later interaction. [Figure 10B](#F0010) summarizes the SR1/*ahrC*/CsrA regulatory cascade.10.1080/15476286.2019.1605811-F0009Figure 9.Complex formation between wild-type and mutant SR1 and *ahrC* mRNA species in the presence and absence of CsrA.1 µM CsrA was employed if indicated and complex formation monitored as described in *Materials and Methods*. The internally α ^32^\[P\]-\[UTP\] labelled SR1 species (0.15 fmol per reaction) were used in at least 100-fold lower equimolar amounts compared to the unlabelled *ahrC* mRNA species. Used *ahrC* mRNA concentrations are indicated. (a) Complex formation between SR1~WT~ and *ahrC*~WT~ mRNA. (b) Complex formation between SR1~mut2~ and *ahrC*~WT~ mRNA. (c) Complex formation between SR1~WT~ and *ahrC*~mut1~ mRNA (d) Complex formation between SR1~WT~ and *ahrC*~mut2+3~ mRNA. Autoradiograms of the gels are shown. Below the gels, the percentage of SR1/*ahrC* mRNA complexes calculated with the AIDA software (Raytest) is indicated.10.1080/15476286.2019.1605811-F0010Figure 10.Function of CsrA in the SR1/*ahrC* mRNA system.(a) Working model on the mechanism of CsrA action. SR1 binds *ahrC* mRNA within 7 complementary regions (A-G). *ahrC* mRNA region G' responsible for the initial contact is partially sequestered in a short stem loop structure. In the absence of CsrA breathing of the stem loop structure opens G' and allows inefficient binding of SR1. The interaction with SR1 induces structural changes within *ahrC* mRNA which prevent translation initiation. The presence of CsrA increases the SR1 mediated repression of *ahrC* mRNA translation as it facilitates the SR1/*ahrC* mRNA interaction. Initial CsrA binding to GGA1\* and 3\* opens *ahrC* region G' which allows a more efficient SR1 binding and, hence, a more efficient repression of *ahrC* translation. Binding of additional CsrA molecules to GGA2 and 3 in SR1 and other GGA\*s in *ahrC* mRNA that could further promote complex formation or stabilize the SR1/*ahrC* mRNA complex is conceivable. Yellow boxes: GGA motifs (numbering according to [Figure 1](#F0001)); orange box: initial SR1/*ahrC* interacting regions G and G'; grey boxes: additional SR1/*ahrC* interacting regions; green circle: CsrA. (b) Flow diagram representing the regulatory functions of CcpN, SR1, CsrA and AhrC. CcpN is a transcription factor that represses *sr1* transcription under gluconeogenic conditions \[[28](#CIT0028)--[30](#CIT0030)\]. SR1 is a trans-encoded regulatory RNA that binds *ahrC* mRNA thus inhibiting translation \[[7](#CIT0007),[8](#CIT0008)\]. AhrC is the transcriptional activator of the *rocABC* and *rocDEF* operons \[[7](#CIT0007),[27](#CIT0027)\]. For its activity, it has to bind L-arginine \[[27](#CIT0027)\]. CsrA promotes the base-pairing interaction between SR1 and *ahrC* mRNA (see [Fig. 10A](#F0010)).

Even high concentrations of *hag* mRNA do not interfere with the ability of CsrA to promote the SR1/*ahrC* mRNA interaction {#S0002-S2010}
---------------------------------------------------------------------------------------------------------------------------

To date, *hag* is the only published target of CsrA in *B. subtilis* \[[22](#CIT0022),[23](#CIT0023),[31](#CIT0031)\]. While *hag* mRNA is present under most conditions in high intracellular amounts \[[32](#CIT0032)\] , SR1 is only present in significant intracellular amounts under gluconeogenic conditions with 200--225 molecules/cell \[[8](#CIT0008)\] and under conditions of sporulation \[[32](#CIT0032)\].

To compare the binding affinity of CsrA to SR1 with that to *hag* RNA, experiments with equimolar amounts of two labelled RNAs in the same reaction were employed to investigate the binding preference of CsrA to SR1, *ahrC* mRNA and *hag* RNA (Fig. S7A). SR1 or *ahrC* mRNA in the presence of *hag* RNA, where all were labelled and adjusted to 400 nM, were mixed and incubated with increasing amounts of CsrA. In both cases, *hag* RNA was already bound by CsrA at much lower concentrations (0.1 µM CsrA) than SR1 (0.7 µM CsrA) or *ahrC* mRNA (0.4 µM CsrA), confirming a higher affinity of CsrA to *hag* RNA. This is in accordance with the previously determined K~d~ of 115 nM \[[33](#CIT0033)\] . In conclusion, *hag* RNA was significantly more efficient in binding CsrA than either SR1 or *ahrC* mRNA.

Since the higher affinity of CsrA to *hag* mRNA might interfere with CsrA binding to *ahrC* mRNA or SR1, we investigated whether CsrA can promote the interaction of SR1 and *ahrC* mRNA in the presence of an excess amount of *hag* RNA. As shown in Fig. S7B, there is no difference in the amount of SR1/*ahrC* mRNA complex formed even in the presence of 800 nM *hag* RNA. Thus, although *hag* RNA (800 nM) is present at a two-fold higher concentration than *ahrC* mRNA (400 nM), it does not interfere with the ability of CsrA to promote the SR1/*ahrC* mRNA interaction. In summary, the higher affinity of CsrA for *hag* mRNA does not impede CsrA in promoting complex formation between SR1 and *ahrC* mRNA.

CsrA does not bind to three other currently known trans-encoded sRNAs from *B.* *subtilis* {#S0002-S2011}
------------------------------------------------------------------------------------------

To investigate if SR1 is the only one of the four currently well-characterized trans-encoded sRNAs from *B. subtilis* that is bound by CsrA, we employed EMSA on FsrA \[[34](#CIT0034)\], RnaC \[[35](#CIT0035)\] and RoxS \[[33](#CIT0033)\] in parallel to SR1 (Fig. S8). Three CsrA concentrations between 0.04 and 1 µM were used. Whereas about 40% of SR1 were bound at 0.2 µM, and about 70% at 1 µM, no complex between CsrA and any of the other sRNAs was detectable. Therefore, we can conclude that CsrA does not seem to play a role in the function of these sRNAs.

Discussion {#S0003}
==========

Whereas in Gram-negative bacteria, in particular enterobacteria, the abundant RNA chaperone Hfq plays an important role in sRNA-mediated gene regulation \[[36](#CIT0036),[37](#CIT0037)\], in Gram-positive species, this was only observed in one instance, in *Listeria monocytogenes* \[[38](#CIT0038)\]. Neither we nor others found a role of Hfq in either stabilizing an sRNA or promoting an sRNA/target RNA interaction in *B. subtilis* or *S. aureus* \[[8](#CIT0008),[39](#CIT0039)\]. Streptococcus species do not even encode Hfq. Furthermore, by testing \>150 conditions, no effect of Hfq on posttranscriptional regulation in *B. subtilis* could be observed \[[40](#CIT0040)\] and only six out of 100 known or predicted sRNAs displayed an altered abundance in the absence of Hfq \[[41](#CIT0041)\]. Therefore, it can be assumed that another protein might fulfil the function of Hfq in Gram-positive bacteria.

CsrA is an RNA binding protein that has been predominantly investigated in Gram-negative bacteria as a regulator of mRNA translation or RNA processing. More recently discovered roles of CsrA reviewed by Vakulskas et al. \[[14](#CIT0014)\] include the protection of an mRNA against an RNase \[[19](#CIT0019)\] or revealing a *rut* site required for rho-dependent transcription termination \[[20](#CIT0020)\]. In *B. subtilis*, the flagellin encoding *hag* mRNA was so far the only RNA for which a role of CsrA had been discovered. It contains two CsrA binding sites, one upstream of and one overlapping the SD sequence \[[42](#CIT0042)\]. The location of these motifs corresponds to those in CsrA-regulated mRNAs in Gram-negative bacteria and allows translation inhibition of *hag* mRNA by CsrA \[[42](#CIT0042)\]. Here, we demonstrate that CsrA can promote the complex formation between a regulatory sRNA and its partially complementary target mRNA *in vitro* ([Fig. 5](#F0005)) which has profound consequences *in vivo* ([Figs. 6](#F0006), [8](#F0008)). This is a completely novel role for CsrA not only in *B. subtilis*, but in bacteria in general. Interestingly, such a role has been anticipated recently based on the results of an integrated transcriptomics study \[[21](#CIT0021)\]. We show that CsrA can bind both the small regulatory RNA SR1 and its primary target, *ahrC* mRNA, at nanomolar range ([Fig. 2](#F0002), S1). *In vitro*, CsrA promotes the interaction of both RNAs even in the presence of an excess of *hag* mRNA (Fig. S7) although *hag* mRNA binds CsrA with a higher affinity than SR1 or *ahrC* mRNA \[[42](#CIT0042)\]. In *B. subtilis*, under most conditions, *hag* mRNA is much more abundant than *ahrC* mRNA or SR1 \[[8](#CIT0008),[34](#CIT0034)\]. However, it is unlikely that *hag* mRNA significantly impairs the formation of the ternary SR1/*ahrC* mRNA/CsrA complex *in vivo*. First, under the conditions for *sr1* expression, gluconeogenesis \[[6](#CIT0006),[8](#CIT0008)\] and sporulation \[[34](#CIT0034)\], *hag* mRNA abundance is decreased to levels comparable to SR1 \[[34](#CIT0034)\]. Second, CsrA should not be a limiting component, since micromolar concentrations were measured in *E. coli* \[[42](#CIT0042)\] and estimated in *B. subtilis* (not shown).

How might CsrA promote the interaction between SR1 and *ahrC* mRNA? *B. subtilis* CsrA binds to SR1 GGA motif 2 in a single-stranded region. In *ahrC* mRNA, motifs 1 and 3 contain two single-stranded nt, and motif 2 only one, and, when all mutated, prevent CsrA binding of the *ahrC~136~* mRNA 62--95 nt downstream of the AUG start codon ([Fig. 2C](#F0002)). Interestingly, binding of CsrA to *ahrC~136~* mRNA induced structural changes upstream of GGA2\* ([Fig. 3D](#F0003)) that make nt C~113~ and U~118~ flanking region G' more accessible to the initial contact with region G of SR1 \[[7](#CIT0007)\]. Analysis of the AhrC-regulated p*~rocABC~* promoter confirmed that GGA1\* and GGA3\* are important for CsrA binding to *ahrC* RNA *in vivo* ([Fig. 6B](#F0006)). Regulation by SR1 was impaired when these motifs were mutated although they reside outside of region G' complementary to SR1 region G. Unexpectedly, the alteration of decisive CsrA binding motif 2 of SR1 (pGKSR1~mut2~) resulted in only a minor effect on p*~rocABC~* activity ([Fig. 6B](#F0006)). This was in line with CsrA still being able to promote complex formation despite a 30% reduced binding affinity of SR1~mut2~ to *ahrC~WT~* mRNA ([Fig. 9B](#F0009)). Apparently, initial binding of CsrA to SR1 motif 2 is not required to enhance SR1/*ahrC* mRNA complex formation, whereas binding to *ahrC* mRNA is. Instead, CsrA might restructure *ahrC* mRNA to allow SR1 to access its initial binding site G'.

The NMR solution structure of RsmE -- the CsrA functional homologue from *P. fluorescens* -- bound to its target sites in *hcnA* mRNA revealed that a single protein dimer clamps two target sites, one at the SD sequence and the second upstream of it \[[43](#CIT0043)\]. Indeed, in the majority of cases in Gram-negative bacteria, two binding sites in a distance between 10 and 63 nt have been found to be bridged by one CsrA or Rsm homodimer. This might also apply to binding sites 1 and 3 in *ahrC* mRNA that are located 23 nt apart. As we have shown previously, SR1 binding ≈90 nt downstream of the *ahrC* start codon induces structural alterations at the RBS, which eventually inhibit translation initiation \[[8](#CIT0008)\]. Now we demonstrate that binding of CsrA to at least two sites in *ahrC* RNA (between 72 and 100 nt downstream of the SD sequence) enhances SR1/*ahrC* mRNA base-pairing about two-fold and propose that this allows SR1 to induce the structural alterations that prevent 30S subunit binding to the *ahrC* RBS. Indeed, the 5ʹ CsrA binding motifs 1 to 3 in *ahrC* mRNA flank the G' region, which is the initial interaction site between SR1 and *ahrC* mRNA \[[7](#CIT0007)\]. EMSAs with SR1~WT~ and *ahrC~mut1~* suggest that *ahrC* GGA1\* might be bound first by CsrA, as CsrA was not able to facilitate pairing with SR1~WT~ when this motif was mutated ([Fig. 9C](#F0009)). Based on the EMSAs with *ahrC*~mut2+3~ or *ahrC~mut1/2/3~* ([Fig. 2C](#F0002), [9D](#F0009), S6) we hypothesize that subsequently, CsrA interacts with GGA3\* which opens up region G' required for the initial contact with SR1 \[[8](#CIT0008)\]. GGA2 and GGA3 in SR1 are located between complementary regions C and E, which interact later with C' and E' in *ahrC* mRNA. However, C and E contribute substantially to the formation of the SR1/*ahrC* mRNA duplex, as combined mutations in C, E and F completely abolished duplex formation \[[8](#CIT0008)\]. The importance of these regions for target RNA binding was also corroborated by the 30% reduced ability of SR1~mut2~ to interact with *ahrC~WT~* RNA. As this point mutation did not impede CsrA to promote complex formation with *ahrC~WT~* RNA we suggest that CsrA might bind GGA2 later during interaction of SR1 regions A to F with *ahrC* regions A' to F', bridging it with one of the downstream GGA\* motifs in *ahrC* mRNA, thus stabilizing the SR1/*ahrC* mRNA complex during its formation. [Figure 10A](#F0010) presents a working model on the role of CsrA in the SR1/*ahrC* mRNA system. Alternatively, CsrA binding to SR1 might not be necessary at all for enhancing complex formation, but required for the regulation of other, still unidentified SR1 targets. On average, trans-encoded sRNAs have at least five targets, some of them even more than 40 \[[1](#CIT0001)\]. Since *ahrC* mRNA is currently the only known target of SR1, we cannot rule out this alternative.

Since the regulatory system SR1/*ahrC*/CsrA controls arginine catabolism, we investigated growth in minimal media with and without arginine ([Fig. 8A](#F0008)). As expected, overexpression of *sr1* from pGKSR1 impaired the use of arginine as sole carbon source. This is consistent with SR1 inhibiting translation of *ahrC* mRNA encoding the transcription activator of the arginine catabolic operons \[[8](#CIT0008)\] ([Fig. 4C](#F0004),[D](#F0004)). Deletion of *csrA* relieved growth impairment ([Fig. 8A](#F0008)) confirming that CsrA is an integral part of the regulatory system. When CsrA binding motifs 1 and 3 of *ahrC* were mutated, growth was not impaired in the presence of CsrA ([Fig. 8B](#F0008)). This substantiates that CsrA cannot bind *ahrC~mut1/3~* mRNA at these crucial motifs. Furthermore, whereas *sr1* overexpression inhibited the growth of the wild-type, it did not affect the growth of the *ahrC~mut1/3~* strain confirming again that CsrA binding is the prerequisite for efficient SR1 binding to *ahrC* mRNA ([Fig. 8B](#F0008)). These data together with the results shown in [Fig. 4D](#F0004) further prove the concerted action of CsrA and SR1 in regulating *ahrC.*

Recently, ProQ was discovered to be a new RNA chaperone in Gram-negative bacteria \[[44](#CIT0044),[45](#CIT0045)\]. Chromosome-encoded ProQ belongs to the same family as FinO encoded on F and R1 plasmids (rev. in \[[46](#CIT0046)\]) that enhances -- like Hfq -- the interaction between an antisense RNA (FinP) and its target *traJ* mRNA \[[47](#CIT0047)\]. Recently, it was shown that ProQ promotes the interaction between the sRNA RaiZ and its target, *hu-*α mRNA, to inhibit its translation \[[48](#CIT0048)\]. However, ProQ is not encoded in the genomes of Gram-positive bacteria. As mentioned above, no broader role for Hfq could be established in sRNA/target RNA systems in Gram-positives either. Therefore, it cannot be excluded that CsrA which is broadly conserved and annotated in more than 1500 species (rev. in \[[49](#CIT0049)\]) might be a chaperone that fulfils the role of Hfq or ProQ in Gram-positive bacteria. Unfortunately, to date, only three other trans-encoded sRNAs, FsrA, RnaC and RoxS from *B. subtilis*, have been investigated in detail and their target mRNAs identified \[[34](#CIT0034)--[34](#CIT0034)\]. Only RnaC and FsrA contain one GGA motif but do not bind CsrA. In addition, for FsrA it has been speculated that one or more of three small basic proteins, FbpA, B and C, might be the required RNA chaperones \[[34](#CIT0034)\]. However, an RNA binding activity has not been verified experimentally for any of them. Genetic evidence indicates that at least the 48 aa FbpB is required for FsrA to translationally repress the *lutABC* mRNA \[[50](#CIT0050)\]. It is still unclear if the role of FbpA, B or C is confined to the FsrA regulon. Notwithstanding, it cannot be excluded that other sRNAs from *B. subtilis* or other Gram-positive bacteria, whose targets have not yet been identified, might use CsrA as a chaperone to facilitate the interaction with their target mRNAs.

In 2018 it was found that two sRNAs, SgrS and DicF play only an accessory role in regulating the mannose reporter gene *manX* by promoting Hfq binding near the *manX* RBS, so that Hfq itself can directly interfere with ribosome binding \[[51](#CIT0051)\]. In the SgrS/DicF-*manX* case, the RNA chaperone apparently swapped the role with the sRNAs SgrS and DicF. Such an accessory role can, however, be excluded for SR1, as CsrA is unable to repress *ahrC* translation in the absence of SR1 ([Fig. 4C](#F0004),[D](#F0004)).

Lately, it was reported that in the *E. coli* enterocyte effacement locus (LEE) Hfq plays a repressive and CsrA an activating role on *sepL* mRNA \[[52](#CIT0052)\]. However, since the motif required for CsrA binding overlaps the second Hfq interaction site, binding of both chaperones is mutually exclusive. Interestingly, in the SR1/*ahrC* system, control seems to be the opposite way around: Hfq activates *ahrC* translation \[[8](#CIT0008)\], whereas CsrA helps to inhibit *ahrC* translation by promoting SR1/*ahrC* RNA base-pairing. Since Hfq binds nt 17 to 21 of *ahrC* mRNA \[[8](#CIT0008)\] and CsrA binding motifs 1 to 3 are located between nt 98 and 131, binding of both RNA chaperones can occur simultaneously. This is in accordance with the results of the recent extended transcriptome research report, where an effect of *E. coli* CsrA on 11 base-pairing sRNAs was detected by CLIP-Seq and/or RNA abundance studies. Similar to *ahrC* mRNA, for GadY and Spot42, the CsrA binding sites do not overlap with the binding sites for Hfq known to promote the interaction of these sRNAs with their target mRNAs \[[21](#CIT0021)\].

So far, only a few examples are known where both Hfq and CsrA are involved in posttranscriptional control of gene expression. Future research will reveal whether these are exceptions. Most probably, the new role of CsrA in the promotion of sRNA/target RNA pairing will not be restricted to the SR1/*ahrC* case. We aim to use a more global approach to investigate the role of CsrA in sRNA/target RNA systems in *Bacillus subtilis*.

Materials and methods {#S0004}
=====================

Enzymes and chemicals {#S0004-S2001}
---------------------

Chemicals used were of the highest purity available. Q5 DNA polymerase, T7 RNA polymerase, CIP and polynucleotide kinase were purchased from NEB, Firepol Taq polymerase from Solis Biodyne, RNases T1 and T2 from Sigma Aldrich, S1 nuclease from Thermo Scientific and RNase A and RNasin from Promega.

Strains, media and growth conditions {#S0004-S2002}
------------------------------------

*E. coli* strains DH5α \[[53](#CIT0053)\], TOP10 (*∆csrA/∆pgaA*) \[[54](#CIT0054)\] and JVS-00141 (*Δhfq*) were used for cloning and CsrA purification, respectively. *B. subtilis* strains DB104 \[[55](#CIT0055)\] and DB104 (*∆csrA::cat*) (this study) were used for *in vivo* experiments. Complex TY medium (16 g/l Tryptone, 10 g/l yeast extract, 5 g/l NaCl) and CSE minimal medium (70 mM K~2~HPO~4~, 30 mM KH~2~PO~4~, 25 mM (NH~4~)~2~SO~4~, 0.5 mM MgSO~4~, 10 µM MnSO~4~, 22 mg/l Fe ammonium citrate, 3 g/l Na succinate, 4 g/l K glutamate and 10 mg/l histidine) served as cultivation media. For growth experiments in CSE, precultures inoculated from a fresh TY plate were grown in 5 ml liquid TY medium for 2 h, centrifuged, washed and resuspended in 1 ml CSE medium without glucose. Aliquots were used to inoculate 10 ml of CSE, CSE with 0.5% glucose (CSEG) or CSE with 8.7 g/l L-arginine (CSEA) to OD~600~ = 0.1 and grown for 8 h. If necessary, antibiotics were added as follows: For *E. coli* 100 µg/ml ampicillin or 25 µg/ml kanamycin and for *B. subtilis* 100 µg/ml spectinomycin, 5 µg/ml chloramphenicol, 5 µg/ml erythromycin or 12 µg/ml kanamycin.

Protein purification {#S0004-S2003}
--------------------

*E. coli Δhfq* or *ΔcsrA/pgaA* strains containing plasmid pGPPM1 were used for purification of C-terminally Strep-tagged *B. subtilis* CsrA (CsrA~Strep~). Purification was performed as described using the Strep-Tactin system from IBA (Göttingen) \[[9](#CIT0009)\]. CsrA preparations from both strains bound SR1 with the same affinity (Fig. S1).

*In vitro* transcription, preparation of total RNA and Northern blotting {#S0004-S2004}
------------------------------------------------------------------------

*In vitro* transcription was performed as described \[[8](#CIT0008)\]. Two-step PCRs were employed to introduce mutations by exchanging nucleotides of the complementary inner primers (see Table S1). Preparation of total RNA and Northern blotting including the determination of RNA half-lives were carried out as described previously \[[6](#CIT0006)\], except that for qRT-PCR only 125 µl time samples were taken and directly added to 250 µl RNAprotect Bacteria Reagent (Qiagen), vortexed and incubated for 5 min at room temperature. After centrifugation, the pellets were flash-frozen in liquid nitrogen and stored until use at −20°C. The isolated RNA was treated for 1 h at 37°C with 4 µl DNase I (RNase-free, NEB), followed by one phenol and two chloroform extractions. After ethanol precipitation, the RNA was dissolved in 20 µl bidist (bidistilled water).

Analysis of RNA-RNA complex formation and structure probing {#S0004-S2005}
-----------------------------------------------------------

Both SR1 and *ahrC* mRNA were synthesized *in vitro* from PCR-generated template fragments with specific primer pairs (see Table S1 for all oligonucleotides) using T7 RNA polymerase, purified from 6% denaturing PAA gels and resolved in TMN buffer (20 mM Tris-acetate pH 7.5, 2 mM MgCl~2~, 100 mM NaCl). RNAs were incubated for 2 min at 95°C, 2 min on ice followed by 30 min at 37°C to allow for proper folding. For RNA-RNA complex formation, various concentrations of unlabelled target RNA (determined by UV spectrophotometry) were incubated with 2000 cpm of α-^32^P-\[UTP\] labelled SR1 and 0.1 g/l tRNA in TMN buffer for 15 min at 37°C. One volume of stop solution (0.5 x TBE, 10% glycerol, 0.05% bromophenol blue and 0.05% xylene cyanol) was added, the mixtures rapidly cooled on ice, immediately loaded onto a 4%, 6% or 8% native PAA gel containing 1 x TBE buffer and separated in 0.5-fold TBE with 20 mA at 4°C for 4 h. Dried gels were analysed by PhosphorImaging in a Biostep PhosphorImager using AIDA Image Analyzer 5.0 software (Raytest). Structure probing of 5ʹ labelled RNAs was performed as follows: After binding of CsrA~Strep~ to SR1 or *ahrC* RNA (30 000 cpm) in TMN buffer (total volume 5 µl) for 10 min at 37°C, 5 µl 1 x TMN buffer containing the diluted RNase T1, T2, A or S1 nuclease and 0.4 µl tRNA were added and cleavage conducted for 5 min at 37°C. For S1 nuclease cleavage, 2 mM ZnCl~2~ were added. A negative control without RNases was used. The reaction was stopped by addition of one volume formamide loading dye (90% formamide, 15 mM EDTA, 0.05% bromophenol blue and 0.05% xylene cyanole) and incubation on ice. After heat denaturation for 5 min at 95°C, the reaction mix was separated alongside a T1 ladder on a denaturing 8% or 6% PAA gel at 25 mA.

Analysis of CsrA binding to RNA {#S0004-S2006}
-------------------------------

Internally α-^32^P-\[UTP\] labelled SR1 or *ahrC* mRNA were synthesized by T7 RNA polymerase on PCR templates, gel-purified and incubated with different concentrations of CsrA~Strep~ for 10 min at 37°C. Stop solution (10% glycerol, 0.5x TBE, 0.05% bromophenol blue and 0.05% xylene cyanol) was added and samples were separated in native 6% or 8% PAA gels run at 4°C. Dried gels were quantified by PhosphorImaging as above.

cDNA synthesis and qRT-PCR {#S0004-S2007}
--------------------------

10 µl DNase I treated RNA was used for the synthesis of cDNA with 50 U SuperScript II reverse transcriptase (Invitrogen) for 50 min at 42°C, followed by digestion with 1 µl RNase A for 10 min at 37°C. After one phenol and two chloroform extractions followed by ethanol precipitation, the pellet was dissolved in 20 µl bidist. Quantitative real-time PCR was performed with the Maxima SYBR Green/ROX qPCR Master Mix (ThermoFisher) and the Mx3005P system (Stratagene) in 96 well blocks. Each well contained 9 µl bidist, 1.5 µl of primer mix (5 pmol/ml each in bidist) and 2 µl undiluted template cDNA. The reaction was started after addition of 12.5 µl qPCR MasterMix 2x in a darkened room. Forty cycles with denaturation for 30 s at 95°C, annealing for 30 s at 48°C and extension for 30 s at 72°C were used. Only for 5S rRNA detection, the template cDNA was 1000-fold diluted. Immediately after qRT-PCR, a melting point analysis with MxPro software (Stratagene) was carried out to test for product specificity. For final validation, a modified *∆∆*Ct method was employed defining the number of cycles at which the fluorescence exceeds a certain threshold as Ct value. For evaluation, MxProSoftware from Stratagene was used.

Construction of plasmids and strains {#S0004-S2008}
------------------------------------

*E. coli*/*B. subtilis* shuttle vector pGPPM1 (see Table S2 for all plasmids) for constitutive expression and purification of C-terminally Strep-tagged *B. subtilis* CsrA (CsrA~Strep~) was constructed by cloning a BamHI/SphI fragment obtained by PCR with primer pair SB2497/SB2498 on chromosomal DNA of *B. subtilis* into the BamHI/SphI pGP382 vector. The insert sequence was confirmed by sequencing. *B. subtilis* strain DB104 *(∆csrA::spec*) was constructed by transformation of strain DB104 with chromosomal DNA isolated from *B. subtilis* strain GP469. *B. subtilis* strain DB104 (*amyE::pGAB kan)* was constructed by transformation of DB104 with linearized integration vector pGAB1. Plasmid pINT6E constructed by exchanging the chloramphenicol resistance gene of plasmid pINT6 \[[7](#CIT0007)\] by the erythromycin resistance gene of plasmid pE194 was integrated into the *B. subtilis* DB104 chromosome resulting in DB104 (*∆ahrC::ery*). Successful *ahrC* knockout was confirmed by PCR on chromosomal DNA. For the construction of the *csrA*~C-Flag~ strain, long-flanking-homology (LFH) PCR was used. Twenty-five cycles of PCR with Q5 polymerase were employed to generate four PCR fragments. The *csrA* FRONT cassette was obtained with primers SB3063/SB3078, the chloramphenicol resistance gene with SB3079/SB3080, and the *csrA* BACK cassette with SB3081/SB3066. SB3078 and SB3079 contain the sequence for the FLAG-tag to be introduced at the C-terminus of the chromosomally encoded *csrA* gene. After purification from agarose gels, the four fragments were pooled and subjected to 10 cycles with Q5 polymerase without primers for annealing, followed by 25 cycles for amplification with primer pair SB3063/SB3066. The resulting long fragment was directly used to transform DB104 to allow homologous recombination, and selection was performed on TY plates with chloramphenicol. The successful strain construction and expression of *csrA*~C-Flag~ were confirmed by PCR on chromosomal DNA and Western blotting with anti-FLAG antibodies, respectively.

Plasmid pGKSR1~mut2~ carrying a mutation in GGA2 of *sr1* was constructed by a two-step-PCR as follows: Chromosomal DNA of *B. subtilis* DB104 was used as a template to obtain two PCR fragments using primer pairs SB3199/SB1580 and SB1579/SB317, respectively. These fragments were isolated from an agarose gel and subjected to another PCR with primers SB3199 and SB317. The resulting fragment was isolated, digested with BamHI and HindIII and inserted into the BamHI/HindIII vector of pGK14.

The chromosomal *ahrC* mutant altered in GGA1\* (to AGA) and GGA3\* (to GGG) was constructed by LFH PCR as follows: The 900 bp FRONT fragment was generated with primer pairs SB3298/SB3321 and the 400 bp INSERT fragment with SB3320 and SB3307. A 1 kb BACK fragment and a 900 bp kanamycin resistance cassette obtained with SB3317/SB3313 and SB3308/SB3316, respectively, were used. Twenty-five PCR cycles with Q5 polymerase were employed to generate all fragments. The final PCR joining the four fragments was performed with primer pair SB3298/SB3313 as described above for the *csrA*~C-FLAG~ strain. DB104 was transformed directly with the resulting long fragment, and selection was for kanamycin resistance. The mutant was confirmed by sequencing. The LFH PCRs were performed with denaturation for 30 s at 98°C, annealing for 30 s at 42°C and elongation at 72°C for 1 min per expected 1000 bp.

Construction of transcriptional and translational *lacZ* fusions and determination of β-galactosidase activities {#S0004-S2009}
----------------------------------------------------------------------------------------------------------------

For the construction of transcriptional *lacZ* fusions, PCR fragments were obtained on chromosomal DNA as template with primer pairs SB2744/2745 and SB2746/2747, digested with BamHI and EcoRI and inserted into pMG16 \[[56](#CIT0056)\] cleaved with the same enzyme pair yielding pMGP21 (p*~rocABC~*) and pMGP22 (p*~rocDEF~*), respectively. For the construction of translational *lacZ* fusions, PCR fragments were generated with primer pairs SB2774/SB2775 (*ccpN*), SB2778/SB2779 (*rocA*) and SB2780/SB2781 (*rocD*), cleaved with BamHI and EcoRI and inserted into the BamHI/EcoRI pGAB1 vector resulting in pGABP1-3, respectively. In pGABP1-3, transcription is under control of the constitutive heterologous promoter pIII. All vectors carrying *lacZ* fusions were confirmed by sequencing, linearized with ScaI and integrated into the chromosomal *amyE* locus. β-galactosidase activities were measured as described \[[9](#CIT0009)\].

*Construction of B.* *subtilis strains containing* a translational ahrC-lacZ *fusion in the* amyE *locus* {#S0004-S2010}
---------------------------------------------------------------------------------------------------------

For the construction of the *ahrC*~483~*-lacZ* fusion, LFH PCR was used. Four fragments, *amyE* FRONT cassette (SB3027/SB3028, chromosomal DNA as template), *ahrC*~483~ under control of promoter pI (SB3075/SB3062, chromosomal DNA), spectinomycin resistance gene (SB3032/SB3074, pMG8 \[[27](#CIT0027),[57](#CIT0057)\]) and *lacZ* (SB3061/3030, pGAB1), were generated by 25 cycles of PCR with Q5 polymerase. After purification from agarose gels, the four fragments were pooled and subjected to 10 cycles with Q5 polymerase without primers for annealing, followed by 25 cycles for amplification with primer pair SB3027/SB3030. The resulting long fragment was directly used to transform DB104 (*amyE::pGAB kan)* to allow homologous recombination. Selection was performed on TY plates with spectinomycin and X-Gal. To enable later transformation of this strain with *sr1* overexpression plasmid pWSR1 encoding kanamycin resistance (*kan^R^*), the remaining *kan^R^* gene was inactivated by insertion of an erythromycin resistance (*ery^R^*) cassette using LFH PCR as above. FRONT and the BACK cassettes were obtained with SB3391/SB3392 or SB3395/SB3396, respectively, on pGAB1 as template, and the *ery^R^* insert with SB3393/SB23394 on pMG10 \[[57](#CIT0057)\] as template. The resulting long fragment was used to transform DB104 (*amyE::ahrC-lacZ spec kan*) yielding DB104 (*amyE::ahrC-lacZ spec ery*). Selection was for erythromycin resistance and kanamycin sensitivity.

*In vitro* translation {#S0004-S2011}
----------------------

The PURExpress® In Vitro Protein Synthesis Kit (NEB) was used for *in vitro* translation. A full-length *in vitro* transcribed *ahrC* RNA served as template. 10 µl reactions, each containing 2.5 µCi of \[[34](#CIT0034)\] ^35^S-labelled methionine (1000 Ci/mmol), were pipetted as described in the manufacturers' instructions, mixed with 1 µl *ahrC* RNA (300 nM final concentration), either 6 µl CsrA (final concentration 800 nM) or buffer W (IBA) and 1 µl SR1~start\ to\ stop~ (final concentration 3 µM) or bidist and incubated at 32°C for 20 h. Reaction products were separated on a 17.5% Tris/glycine/SDS PAA gel. Dried gels were quantified by PhosphorImaging as above.
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